These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33349575)

  • 1. How do adenosine A
    Mori A
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S13-S20. PubMed ID: 33349575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease.
    Mori A
    Int Rev Neurobiol; 2014; 119():87-116. PubMed ID: 25175962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
    Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can adenosine A
    Kanda T; Jenner P
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists.
    Mori A; Shindou T
    Neurology; 2003 Dec; 61(11 Suppl 6):S44-8. PubMed ID: 14663009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological interactions between adenosine A
    Pinna A; Serra M; Marongiu J; Morelli M
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S37-S44. PubMed ID: 33349579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
    Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
    Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
    Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
    Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions.
    Simola N; Morelli M; Pinna A
    Curr Pharm Des; 2008; 14(15):1475-89. PubMed ID: 18537671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia.
    Kase H
    Biosci Biotechnol Biochem; 2001 Jul; 65(7):1447-57. PubMed ID: 11515525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
    Smith KM; Browne SE; Jayaraman S; Bleickardt CJ; Hodge LM; Lis E; Yao L; Rittle SL; Innocent N; Mullins DE; Boykow G; Reynolds IJ; Hill D; Parker EM; Hodgson RA
    Eur J Pharmacol; 2014 Apr; 728():31-8. PubMed ID: 24486705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of adenosine A
    Pinna A; Serra M; Morelli M; Simola N
    J Neural Transm (Vienna); 2018 Aug; 125(8):1273-1286. PubMed ID: 29396609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
    Stasi MA; Minetti P; Lombardo K; Riccioni T; Caprioli A; Vertechy M; Di Serio S; Pace S; Borsini F
    Eur J Pharmacol; 2015 Aug; 761():353-61. PubMed ID: 25936513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting adenosine A2A receptors in Parkinson's disease.
    Schwarzschild MA; Agnati L; Fuxe K; Chen JF; Morelli M
    Trends Neurosci; 2006 Nov; 29(11):647-54. PubMed ID: 17030429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine A2A-D2 receptor-receptor interactions in putative heteromers in the regulation of the striato-pallidal gaba pathway: possible relevance for parkinson's disease and its treatment.
    Beggiato S; Antonelli T; Tomasini MC; Borelli AC; Agnati LF; Tanganelli S; Fuxe K; Ferraro L
    Curr Protein Pept Sci; 2014; 15(7):673-80. PubMed ID: 25175458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can adenosine A
    Jenner P; Mori A; Kanda T
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S28-S36. PubMed ID: 33349577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
    Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ
    Neurology; 2011 May; 76(21):1811-6. PubMed ID: 21606452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease.
    Shah U; Hodgson R
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):466-80. PubMed ID: 20597030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The treatment of Parkinson's disease--adenosine A2A receptor antagonists].
    Matsubara E; Shoji M; Abe K
    Nihon Rinsho; 2002 Jan; 60(1):112-6. PubMed ID: 11808320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.